Search This Blog

Friday, April 17, 2026

Nkarta, FDA agree on protocol changes for NKX019 Ntrust trials enabling outpatient dosing and redosing

 


  • Agreement covers protocol amendments for Ntrust-1 and Ntrust-2 clinical trials of NKX019.
  • Ntrust-2 protocol amendment adds a new rheumatoid arthritis patient cohort to the study.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)